The England Rare Diseases Action Plan 2026 outlines how the Department of Health and Social Care and partner organisations are delivering commitments under the UK Rare Diseases Framework to improve outcomes for people living with rare conditions in England. The report reviews progress made to date and introduces a new action formally recognising rare disease as a health inequality.
Background and Vision
In the UK, a rare disease is defined as a condition affecting fewer than 1 in 2,000 people. Although individual conditions are uncommon, collectively rare diseases affect a significant proportion of the population, with approximately 1 in 17 people expected to live with a rare condition at some point in their lives.
The UK Rare Diseases Framework, published in 2021, identified four priority areas aimed at addressing long-standing systemic challenges. Since then, annual action plans have translated the framework into targeted initiatives. The 2026 report reflects progress against these priorities and sets direction for the coming year.
The Four Core Priorities
1. Faster Diagnosis
Reducing the “diagnostic odyssey” remains a central objective. The action plan highlights continued expansion of genomic medicine services within the NHS, including the routine use of whole-genome sequencing to identify thousands of rare conditions.
National initiatives, such as newborn genomic screening studies, are designed to detect rare diseases earlier in life. Pilot centres for undiagnosed rare conditions are also progressing, with the aim of providing structured support to patients who have yet to receive a confirmed diagnosis.
2. Increased Awareness Among Healthcare Professionals
Improving awareness and education across the healthcare workforce is another priority. The plan outlines ongoing efforts to integrate rare disease recognition into training pathways and to provide clinicians with better access to genomic and diagnostic tools.
Given that many rare conditions initially present in primary care or non-specialist settings, earlier recognition by frontline professionals is considered critical to improving patient outcomes.
3. Better Coordination of Care
People living with rare diseases often require multidisciplinary care spanning multiple specialties and services. Fragmented pathways can result in delays, duplication and patient burden.
The 2026 plan reports continued development of rare disease collaborative networks and initiatives designed to improve coordination across NHS services. Research into cost-effective models of care coordination is also underway, reflecting recognition that continuity and integration are central to improving long-term outcomes.
4. Improved Access to Specialist Care, Treatments and Drugs
While scientific advances continue, effective treatments exist for only a small percentage of rare diseases. The action plan outlines ongoing work to support equitable access to specialist services, advanced therapies and innovative medicines.
Regulatory and health technology assessment processes remain key components in determining how and when new treatments become available. The report acknowledges both progress and ongoing challenges in ensuring timely patient access.
Recognising Rare Disease as a Health Inequality
A significant development in the 2026 plan is the introduction of a new action formally recognising rare disease as a health inequality. This reflects growing acknowledgment that individuals living with rare conditions frequently experience disproportionate barriers to diagnosis, treatment access and coordinated care.
By framing rare disease within a health inequality context, the government signals an intention to address systemic disparities alongside clinical challenges.
Cross-Cutting Themes
Two themes underpin the entire action plan: health equity and the use of digital, data and technology.
Digital innovation, genomic data infrastructure and improved data sharing are positioned as key enablers of faster diagnosis and more coordinated care. At the same time, reducing geographic and socioeconomic variation in access remains a priority.
Looking Ahead
The 2026 action plan largely builds on existing initiatives rather than introducing a wide range of new commitments. It reinforces long-term objectives under the UK Rare Diseases Framework and signals continued collaboration with patient groups, clinicians and researchers.
While measurable progress has been made in genomic medicine and care coordination, substantial unmet need remains. For many patients, diagnosis is still delayed and treatment options remain limited. The 2026 plan therefore represents both consolidation of progress and recognition that sustained effort will be required to deliver meaningful system-wide change.
